Aim: The aim of our study was to evaluate the outcomes of patients reirradiated with high-dose-rate (HDR) intensity-modulated brachytherapy (IMBT) for recurrent head and neck cancer and to perform a systematic review of the literature. Materials and methods: Patients treated with prior radiation doses > 65 Gy were considered. After resection of macroscopic disease, catheters were fixed to the tumor bed. The total dose was 30 Gy in 12 fractions of 2.5 Gy twice daily for 5 days a week. A systematic literature search was conducted through several electronic databases including Medline/PubMed, Scopus, Embase and the Cochrane library. Results: Seventeen patients were included; median overall survival was 19 months with a median local control interval of 15 months. Median follow-up was 36 months. Seven papers were considered for the review. Conclusions: IMBT could play an important role in the retreatment of recurrent head and neck cancer.
Perioperative HDR brachytherapy for reirradiation in head and neck recurrences: Single-institution experience and systematic review / Tagliaferri, L.; Bussu, F.; Fionda, B.; Catucci, F.; Rigante, M.; Gambacorta, M. A.; Autorino, R.; Mattiucci, G. C.; Micciche, F.; Placidi, E.; Balducci, M.; Galli, J.; Paludetti, G.; Kovacs, G.; Valentini, V.. - In: TUMORI. - ISSN 0300-8916. - 103:6(2017), pp. 516-524. [10.5301/tj.5000614]
Perioperative HDR brachytherapy for reirradiation in head and neck recurrences: Single-institution experience and systematic review
Bussu F.;
2017-01-01
Abstract
Aim: The aim of our study was to evaluate the outcomes of patients reirradiated with high-dose-rate (HDR) intensity-modulated brachytherapy (IMBT) for recurrent head and neck cancer and to perform a systematic review of the literature. Materials and methods: Patients treated with prior radiation doses > 65 Gy were considered. After resection of macroscopic disease, catheters were fixed to the tumor bed. The total dose was 30 Gy in 12 fractions of 2.5 Gy twice daily for 5 days a week. A systematic literature search was conducted through several electronic databases including Medline/PubMed, Scopus, Embase and the Cochrane library. Results: Seventeen patients were included; median overall survival was 19 months with a median local control interval of 15 months. Median follow-up was 36 months. Seven papers were considered for the review. Conclusions: IMBT could play an important role in the retreatment of recurrent head and neck cancer.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
